INTERVENTIONELLE, MEDIKAMENTÖSE STUDIEN
Titel
A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVE) Compared to Obinutuzumab and Venetoclax (GVE) in Previously Untreated Patients With High Risk (17P-deletion, TP53-mutation or Complex Karyotype) Chronic Lymphatic Leukemia (CLL)
Indikation
Chronic Lymphatic Leukemia (CLL)
Art der Studie
Therapiestudie, Interventionell, Phase 3
Therapielinie
Erstlinientherapie
Hauptprüfer am Zentrum (PI)
Prof. Dr. med. C. Dierks
Ansprechpartner
Frau J. Sen
Telefon: 0345/ 557 4853
Mail: ectu@uk-halle.de
Titel
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia
Indikation
Chronic Lymphatic Leukemia (CLL)
Art der Studie
Therapiestudie, Interventionell, Phase 2
Therapielinie
Zweitlinientherapie
Hauptprüfer am Zentrum (PI)
Prof. Dr. med. C. Dierks
Ansprechpartner
Frau A. Kleinbauer
Telefon: 0345/ 557 1386
Mail: antje.kleinbauer@uk-halle.de